Showing results (61-70 of 272) with videos related to

Sort By:
Pageof 28
The Oncologist|May 30, 2019
Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-UpAri Joseph Rosenberg, Alfred Rademaker, Howard S Hochster, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2014
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanomaDevalingam Mahalingam, Laeeq Malik, Muralidhar Beeram, et al.
Acta Oncologica (Stockholm, Sweden)|November 16, 2017
Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT)Bengt Glimelius, Nebojsa Manojlovic, Per Pfeiffer, et al.
Cancer Medicine|April 1, 2025
Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Salivary Gland TumorsYoung Kwang Chae, Richard Duan, Liam Il-Young Chung, et al.
Seminars in Thrombosis and Hemostasis|July 1, 2006
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disordersAlfonso Quintás-Cardama, Hagop M Kantarjian, Francis Giles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Important therapeutic targets in chronic myelogenous leukemiaHagop M Kantarjian, Francis Giles, Alfonso Quintás-Cardama, et al.
Seminars in Hematology|February 13, 2007
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistanceElias Jabbour, Jorge Cortes, Susan O'Brien, et al.
Idrugs : the Investigational Drugs Journal|July 21, 2007
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyondElias Jabbour, Jorge Cortes, Francis Giles, et al.
Drugs in R&D|December 23, 2015
Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid TumorsGerald S Falchook, Xiaofei Zhou, Karthik Venkatakrishnan, et al.
Cancer|January 28, 2004
Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignanciesApostolia-Maria Tsimberidou, Francis Giles, Jorge Romaguera, et al.
Pageof 28